{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:59:35Z","timestamp":1792202375272,"version":"4.4.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gene"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.gene.2018.04.043","type":"journal-article","created":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T02:44:36Z","timestamp":1524019476000},"page":"44-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Association of CYP3A4*1B genotype with Cyclosporin A pharmacokinetics in renal transplant recipients: A meta-analysis"],"prefix":"10.1016","volume":"664","author":[{"given":"Cai-e","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke-Peng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Li","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Ling","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.gene.2018.04.043_bb0005","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1093\/clinchem\/47.6.1048","article-title":"No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients","volume":"47","author":"von Ahsen","year":"2001","journal-title":"Clin. Chem."},{"issue":"3","key":"10.1016\/j.gene.2018.04.043_bb0010","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0009-9236(99)70037-8","article-title":"Population distribution and effects on drug metabolism of a genetic variant in the 5\u2032 promoter region of CYP3A4","volume":"66","author":"Ball","year":"1999","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.gene.2018.04.043_bb0015","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.phrs.2016.07.027","article-title":"Intra-cellular immunosuppressive drugs monitoring: a step forward towards better therapeutic efficacy after organ transplantation?","volume":"111","author":"Capron","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"9","key":"10.1016\/j.gene.2018.04.043_bb0020","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.bcp.2004.07.012","article-title":"In vitro metabolism of cyclosporine A by human kidney CYP3A5","volume":"68","author":"Dai","year":"2004","journal-title":"Biochem. Pharmacol."},{"issue":"13","key":"10.1016\/j.gene.2018.04.043_bb0025","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.2165\/00003495-200161130-00006","article-title":"Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation","volume":"61","author":"Dunn","year":"2001","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.gene.2018.04.043_bb0030","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2217\/pgs.12.187","article-title":"CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy","volume":"14","author":"Elens","year":"2013","journal-title":"Pharmacogenomics"},{"issue":"3","key":"10.1016\/j.gene.2018.04.043_bb0035","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00228-012-1355-x","article-title":"ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients","volume":"69","author":"Garcia","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.gene.2018.04.043_bb0040","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1067\/mcp.2002.121371","article-title":"CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity","volume":"71","author":"Garcia-Martin","year":"2002","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1\u20132","key":"10.1016\/j.gene.2018.04.043_bb0045","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0027-5107(01)00305-0","article-title":"Mutation analysis of the human CYP3A4 gene 5\u2032 regulatory region: population screening using non-radioactive SSCP","volume":"500","author":"Hamzeiy","year":"2002","journal-title":"Mutat. Res."},{"issue":"3","key":"10.1016\/j.gene.2018.04.043_bb0050","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.transproceed.2013.11.060","volume":"46","author":"Hashi","year":"2014","journal-title":"Transplant. Proc."},{"issue":"3","key":"10.1016\/j.gene.2018.04.043_bb0055","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00008571-200403000-00002","article-title":"The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients","volume":"14","author":"Haufroid","year":"2004","journal-title":"Pharmacogenetics"},{"issue":"3","key":"10.1016\/j.gene.2018.04.043_bb0060","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0009-9236(03)00168-1","article-title":"Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus","volume":"74","author":"Hesselink","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.gene.2018.04.043_bb0065","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.clpt.2004.08.022","article-title":"Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes","volume":"76","author":"Hesselink","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.gene.2018.04.043_bb0070","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1517\/14622416.6.4.323","article-title":"The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression?","volume":"6","author":"Hesselink","year":"2005","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.gene.2018.04.043_bb0075","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med. Res. Methodol."},{"issue":"3","key":"10.1016\/j.gene.2018.04.043_bb0080","first-page":"268","article-title":"Novel mutations of CYP3A4 in Chinese","volume":"29","author":"Hsieh","year":"2001","journal-title":"Drug Metab. Dispos."},{"issue":"5","key":"10.1016\/j.gene.2018.04.043_bb0085","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1742-7843.2008.00300.x","article-title":"Meta-analysis of the effect of MDR1 C3435T polymorphism on cyclosporine pharmacokinetics","volume":"103","author":"Jiang","year":"2008","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"4","key":"10.1016\/j.gene.2018.04.043_bb0090","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat. Genet."},{"issue":"6","key":"10.1016\/j.gene.2018.04.043_bb0095","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/sj.clpt.6100216","article-title":"CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients","volume":"82","author":"Kuypers","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.gene.2018.04.043_bb0100","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00008571-200203000-00006","article-title":"Common allelic variants of cytochrome P4503A4 and their prevalence in different populations","volume":"12","author":"Lamba","year":"2002","journal-title":"Pharmacogenetics"},{"issue":"10","key":"10.1016\/j.gene.2018.04.043_bb0105","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0169-409X(02)00066-2","article-title":"Genetic contribution to variable human CYP3A-mediated metabolism","volume":"54","author":"Lamba","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.gene.2018.04.043_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000022","article-title":"STrengthening the REporting of Genetic Association Studies (STREGA): an extension of the STROBE statement","volume":"6","author":"Little","year":"2009","journal-title":"PLoS Med."},{"issue":"3","key":"10.1016\/j.gene.2018.04.043_bb0115","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00007691-200306000-00010","article-title":"Association of the CYP3A4*1B 5\u2032-flanking region polymorphism with cyclosporine pharmacokinetics in healthy subjects","volume":"25","author":"Min","year":"2003","journal-title":"Ther. Drug Monit."},{"issue":"4","key":"10.1016\/j.gene.2018.04.043_bb0120","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/j.1472-8206.2007.00504.x","article-title":"Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms","volume":"21","author":"Op den Buijsch","year":"2007","journal-title":"Fundam. Clin. Pharmacol."},{"issue":"10","key":"10.1016\/j.gene.2018.04.043_bb0125","first-page":"901","article-title":"Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients","volume":"8","author":"Paris","year":"1999","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"issue":"5","key":"10.1016\/j.gene.2018.04.043_bb0130","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s002280000166","article-title":"Frequency of cytochrome P450 3A4 variant genotype in transplant population and lack of association with cyclosporin clearance","volume":"56","author":"Rivory","year":"2000","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.gene.2018.04.043_bb0135","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1067\/mcp.2000.104391","article-title":"CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity","volume":"67","author":"Sata","year":"2000","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.gene.2018.04.043_bb0140","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00210-009-0415-y","article-title":"Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India","volume":"380","author":"Singh","year":"2009","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"issue":"11","key":"10.1016\/j.gene.2018.04.043_bb0145","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2217\/pgs.13.116","article-title":"DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis","volume":"14","author":"Terrazzino","year":"2013","journal-title":"Pharmacogenomics"},{"issue":"9","key":"10.1016\/j.gene.2018.04.043_bb0150","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/sim.2010","article-title":"A method for meta-analysis of molecular association studies","volume":"24","author":"Thakkinstian","year":"2005","journal-title":"Stat. Med."},{"issue":"4","key":"10.1016\/j.gene.2018.04.043_bb0155","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3109\/10408368709105886","article-title":"Cyclosporine: structure, pharmacokinetics, and therapeutic drug monitoring","volume":"25","author":"Vine","year":"1987","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"issue":"4","key":"10.1016\/j.gene.2018.04.043_bb0160","first-page":"289","article-title":"Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online","volume":"12","author":"Walker","year":"1998","journal-title":"Hum. Mutat."},{"issue":"8","key":"10.1016\/j.gene.2018.04.043_bb0165","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/jnci\/94.8.630","article-title":"Re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4","volume":"94","author":"Wojnowski","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.gene.2018.04.043_bb0170","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/14728214.2017.1330884","article-title":"Emerging drugs for prevention of T-cell mediated rejection in liver and kidney transplantation","volume":"22","author":"Wong","year":"2017","journal-title":"Expert Opin. Emerg. Drugs"},{"issue":"5","key":"10.1016\/j.gene.2018.04.043_bb0175","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.thromres.2013.09.005","article-title":"Who are at risk for thromboembolism after arthroplasty? A systematic review and meta-analysis","volume":"132","author":"Zhou","year":"2013","journal-title":"Thromb. Res."},{"issue":"3","key":"10.1016\/j.gene.2018.04.043_bb0180","doi-asserted-by":"crossref","first-page":"36","DOI":"10.12659\/AOT.883456","article-title":"Impact of CYP3A4*1B and CYP3A5*3 polymorphisms on the pharmacokinetics of cyclosporine and sirolimus in renal transplant recipients","volume":"17","author":"Zochowska","year":"2012","journal-title":"Ann. Transplant."}],"container-title":["Gene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111918304116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111918304116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T22:21:59Z","timestamp":1604182919000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378111918304116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":36,"alternative-id":["S0378111918304116"],"URL":"https:\/\/doi.org\/10.1016\/j.gene.2018.04.043","relation":{},"ISSN":["0378-1119"],"issn-type":[{"value":"0378-1119","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of CYP3A4*1B genotype with Cyclosporin A pharmacokinetics in renal transplant recipients: A meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Gene","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gene.2018.04.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}